TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Key Stats

• Today's Range: $5.50 to $5.78
• 50-Day Range: $4.69 to $5.77
• 52-Week Range: $3.50 to $10.42
• Volume: 40,590 shs
• Average Volume: 33,834 shs
• Market Capitalization: $173.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.56
• Consensus Rating: Buy

TriSalus Life Sciences Stock Analysis - MarketRank™

TriSalus Life Sciences scored higher than 69% of companies evaluated by MarketBeat, and ranked 331st out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TriSalus Life Sciences is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TriSalus Life Sciences is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 75.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TriSalus Life Sciences does not currently pay a dividend.

Dividend Growth

TriSalus Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.19% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 75.34%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.91

News Sentiment

TriSalus Life Sciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for TriSalus Life Sciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for TLSI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

11 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, TriSalus Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $544,607.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

32.80% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

TLSI Stock Analysis - Frequently Asked Questions

How have TLSI shares performed this year?

TriSalus Life Sciences' stock was trading at $5.01 at the beginning of the year. Since then, TLSI shares have increased by 13.8% and is now trading at $5.70.
View the best growth stocks for 2025 here.

Who are TriSalus Life Sciences' major shareholders?

Top institutional shareholders of TriSalus Life Sciences include Geode Capital Management LLC (0.67%), Bank of America Corp DE (0.59%), Millennium Management LLC (0.26%) and Bridgeway Capital Management LLC (0.21%). Insiders that own company stock include Equity Ab Frankenius, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, James Emmett Young and Mats Wahlstrom.
View institutional ownership trends.

How do I buy shares of TriSalus Life Sciences?

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TriSalus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

• Today: 3/04/2025
• Next Earnings (Confirmed): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TLSI
• Previous Symbol: NASDAQ:TLSI
• CIK: 1826667
• Web: trisaluslifesci.com
• Phone: 888-321-5212
• Fax: N/A
• Employees: 106
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.56
• High Stock Price Target: $16.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +104.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,040,000.00
• Net Margins: -206.24%
• Pretax Margin: -205.69%
• Return on Equity: N/A
• Return on Assets: -236.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.40
• Quick Ratio: 2.00

Sales & Book Value

• Annual Sales: $26.89 million
• Price / Sales: 6.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.98) per share
• Price / Book: -5.77

Miscellaneous

• Outstanding Shares: 30,493,000
• Free Float: 20,491,000
• Market Cap: $172.29 million
• Optionable: Not Optionable
• Beta: 0.51